Spero therapeutics announces second quarter 2024 operating results and provides a business update

Cambridge, mass., aug. 05, 2024 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial results for the second quarter ended june 30, 2024, and provided a business update.
SPRO Ratings Summary
SPRO Quant Ranking